Galectin Therapeutics Inc. (GALT) Trading Up 7.3%
Galectin Therapeutics Inc. (NASDAQ:GALT)’s share price was up 7.3% on Monday . The stock traded as high as $2.25 and last traded at $2.20, with a volume of 206,461 shares changing hands. The stock had previously closed at $2.05.
Several equities analysts have weighed in on GALT shares. HC Wainwright reissued a “buy” rating on shares of Galectin Therapeutics in a report on Thursday, May 12th. FBR & Co restated a “buy” rating on shares of Galectin Therapeutics in a research report on Thursday, May 19th. Zacks Investment Research downgraded Galectin Therapeutics from a “buy” rating to a “sell” rating in a research report on Friday, May 20th. Finally, Roth Capital initiated coverage on Galectin Therapeutics in a research report on Friday, July 1st. They set a “buy” rating on the stock. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Galectin Therapeutics currently has a consensus rating of “Buy” and an average target price of $8.58.
The stock has a 50 day moving average price of $1.62 and a 200 day moving average price of $1.45. The firm’s market cap is $56.02 million.
Galectin Therapeutics (NASDAQ:GALT) last announced its quarterly earnings data on Tuesday, August 9th. The company reported ($0.20) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.04. Analysts expect that Galectin Therapeutics Inc. will post ($0.97) EPS for the current fiscal year.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.